Ivacaftor

Drug Profile

Ivacaftor

Alternative Names: Kalydeco; Potentiator VX-770; VX-770

Latest Information Update: 07 Dec 2016

Price : $50

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Vertex Pharmaceuticals
  • Developer Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cystic fibrosis

Most Recent Events

  • 27 Oct 2016 Positive safety data from the phase III KIWI and KLIMB trials in Cystic fibrosis (In children, Monotherapy) released by Vertex
  • 18 Oct 2016 Vertex Pharmaceuticals initiates enrolment in a phase III trial for Cystic fibrosis (Combination therapy, In children) in USA (PO) (NCT02953314)
  • 01 Oct 2016 Vertex initiates enrolment in a phase II trial for Cystic fibrosis (Combination therapy) in USA (NCT02951182)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top